4.5 Article

Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma Recommendations From the Pancreatobiliary Pathology Society

期刊

AMERICAN JOURNAL OF SURGICAL PATHOLOGY
卷 46, 期 6, 页码 754-764

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PAS.0000000000001853

关键词

pancreatic ductal adenocarcinoma; neoadjuvant therapy; gross examination; mapping sections; tumor size; tumor response grade; survival; lymph node metastasis

资金

  1. National Institutes of Health [1R01CA196941, 1R01CA195651, U01CA196403, P01CA117969, P50CA221707, K08CA234222]

向作者/读者索取更多资源

This study provides recommendations for the pathologic evaluation of posttherapy pancreatectomy specimens, emphasizing the need for systematic and standardized approaches, accurate tumor size measurement, and reproducible tumor response grading. The study also highlights the importance of future research on lymph node metastases, molecular and/or immunohistochemical markers, and the application of artificial intelligence in grading tumor response.
Currently, there are no internationally accepted consensus guidelines for pathologic evaluation of posttherapy pancreatectomy specimens. The Neoadjuvant Therapy Working Group of Pancreatobiliary Pathology Society was formed in 2018 to review grossing protocols, literature, and major issues and to develop recommendations for pathologic evaluation of posttherapy pancreatectomy specimens. The working group generated the following recommendations: (1) Systematic and standardized grossing and sampling protocols should be adopted for pancreatectomy specimens for treated pancreatic ductal adenocarcinoma (PDAC). (2) Consecutive mapping sections along the largest gross tumor dimension are recommended to validate tumor size by histology as required by the College of American Pathologists (CAP) cancer protocol. (3) Tumor size of treated PDACs should be measured microscopically as the largest dimension of tumor outer limits that is bound by viable tumor cells, including intervening stroma. (4) The MD Anderson grading system for tumor response has a better correlation with prognosis and better interobserver concordance among pathologists than does the CAP system. (5) A case should not be classified as a complete response unless the entire pancreas, peripancreatic tissues, ampulla of Vater, common bile duct, and duodenum adjacent to the pancreas are submitted for microscopic examination. (6) Future studies on tumor response of lymph node metastases, molecular and/or immunohistochemical markers, as well as application of artificial intelligence in grading tumor response of treated PDAC are needed. In summary, systematic, standardized pathologic evaluation, accurate tumor size measurement, and reproducible tumor response grading to neoadjuvant therapy are needed for optimal patient care. The criteria and discussions provided here may provide guidance towards these goals.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据